Text 1 — Alzheimer's Disease

Alzheimer's disease is best understood as a systems-level failure emerging from molecular events that progressively destabilize neural computation. The classical amyloid cascade hypothesis identifies aggregation-prone amyloid-β peptides as initiators, but current theory frames pathology as a coupled process in which soluble oligomers impair synaptic signaling while intracellular tau pathology mediates local toxicity and network spread. Two regulatory mechanisms---proteostasis and neuroimmune control---anchor this account. Proteostasis fails when production, clearance, and degradation of misfolded proteins fall out of equilibrium; neuroimmune control is compromised when microglial responses, meant to contain debris, shift toward chronic activation that remodels synapses. Equilibration across these subsystems collapses gradually, not abruptly, which explains why cognition can appear stable while molecular indices change early. At the molecular scale, amyloidogenic processing of the amyloid precursor protein yields longer peptides that oligomerize and disrupt long-term potentiation. Tau, a microtubule-associated protein, dissociates from axons, and accumulates in dendrites where it blocks trafficking and local translation. These processes are more than parallel tracks: amyloid-β can accelerate tau misfolding. The causal claim here is not that one protein alone "causes" dementia, but that specific interactions between proteostasis and neuroimmune signaling push circuits across thresholds of functional resilience.

Methodological progress has reshaped diagnosis and trial design. The AT(N) framework aligns biomarkers for amyloid, tau, and neurodegeneration with clinical staging, enabling improved sampling and earlier intervention. Cerebrospinal fluid ratios of amyloid-β and phosphorylated tau track pathology, while tau-PET resolves regional burden with tractable links to symptom profiles. Blood-based measurements extend this logic to scalable screening, supporting longitudinal designs that follow biomarker trajectories before strong decline. Crucially, the field has acknowledged the mismatch between molecular endpoints and lived outcomes; trials increasingly combine biomarker change with sensitive cognitive composites and daily-function measures to test whether shifting the biology translates into behavior. The psychological picture mirrors how the brain's network breaks down. Early damage in the hippocampus and posterior cingulate weakens the ability to link parts of an experience and to split a stream of activity into meaningful events. As a result, recalling specific episodes drops more than recalling general facts. As long-range connections among fronto-parietal control areas loosen, executive control fades: people switch tasks more slowly, miss errors, and fall back on habits that do not fit the moment. Changes in mood and motivation---apathy, irritability, anxiety---come from disrupted interaction between the brain's "what matters" network and its inward-looking default network; they are not just reactions to memory loss. These effects follow directly from the disease process: when tau builds up in regions that normally combine internal expectations with sensory input, the brain gives too little weight to new evidence, everyday surprises fail to update beliefs, and rigid routines crowd out flexible problem solving.

Randomized trials now show that shifting the early disease process can modestly change the clinical course. Monoclonal antibodies that bind clumped amyloid lower plaque levels and slow the growth of cognitive and functional problems; across carefully followed groups, decline on broad summary measures is reduced by about a quarter. The effect is noticeable but limited by differences in disease stage and other conditions. The causal link is clear at the mechanism level---target engagement comes first, then the slope of decline changes---yet it is not uniform across people: those with heavy tau or significant vascular disease tend to benefit less. Vascular and metabolic factors are central to both cause and treatment. Long-term studies link midlife high blood pressure, insulin resistance, and broken sleep to later amyloid and tau build-up, likely through poorer brain waste clearance and ongoing inflammation. Steps that normalize blood pressure, improve blood sugar control, and stabilize sleep can shift the path of decline; pooled analyses tie intensive vascular risk control to roughly a fifteen percent lower rate of later dementia. Two mechanisms likely explain this: fewer tiny strokes keep networks connected, and better pulse-driven waste clearance supports the brain's protein clean-up, which also makes disease-modifying treatments work better.